๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for High Grade Epithelial Ovarian Cancer

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites๐Ÿ“ Beverly Hills๐Ÿ“ San Francisco๐Ÿ“ Westwood, Los Angeles Fore Biotherapeutics ยท Tests: Plixorafenib Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer NCT06976892Phase 13 sites๐Ÿ“ Cambridge๐Ÿ“ Sutton๐Ÿ“ Cardiff Institute of Cancer Research, United Kingdom ยท Tests: Dose Level 2 (starting dose), Dose Level 1, Dose Level -1, Dose Level 3, Maximum Tolerated Dose Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer NCT04518501Phase 1, Phase 21 site๐Ÿ“ Zhejiang Xing Xie ยท Tests: Arsenic trioxide Tablet +Fuzuloparib Capsules Prehabilitation in High-risk Oncologic Surgery NCT07638410NA1 site๐Ÿ“ Philadelphia Fox Chase Cancer Center ยท Tests: Multidisciplinary Prehabilitation Program Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary NCT06883487n/a1 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: No intervention A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC NCT04644289Phase 26 sites๐Ÿ“ Mannheim๐Ÿ“ Mรผnchen๐Ÿ“ Essen AGO Research GmbH ยท Tests: olaparib, durvalumab AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer NCT07218809Phase 3299 sites๐Ÿ“ Birmingham๐Ÿ“ Little Rock๐Ÿ“ La Jolla AstraZeneca ยท Tests: AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer NCT07125391Phase 21 site๐Ÿ“ Hefei Bai-Rong Xia ยท Tests: Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer NCT05009082Phase 365 sites๐Ÿ“ Amberg๐Ÿ“ Augsburg๐Ÿ“ Bad Homburg AGO Study Group ยท Tests: Carboplatin, Paclitaxel, Bevacizumab, Niraparib Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT07665515Phase 110 sites๐Ÿ“ Cambridge๐Ÿ“ Edinburgh๐Ÿ“ Glasgow Epitopea Ltd ยท Tests: CryptiVax-1001 Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314Phase 3695 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage NRG Oncology ยท Tests: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer NCT06710288Phase 22 sites๐Ÿ“ El Segundo๐Ÿ“ Newport Beach ImmunityBio, Inc. ยท Tests: Gemcitabine, N-803, M-CENK A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025Phase 2, Phase 3167 sites๐Ÿ“ Anchorage๐Ÿ“ New Haven๐Ÿ“ Coral Gables Daiichi Sankyo ยท Tests: R-DXd, Paclitaxel, Topotecan, PLD Mesenteric Infiltration in Ovarian Cancer NCT06331130n/a1 site๐Ÿ“ Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS ยท Tests: Computed Tomography Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer NCT07736937Phase 1, Phase 28 sites๐Ÿ“ Los Angeles๐Ÿ“ East Brunswick๐Ÿ“ New York Gilead Sciences ยท Tests: TUB-040 + Carbo + BEV Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer NCT07371104Phase 11 site๐Ÿ“ Seoul Daewoong Pharmaceutical Co. LTD. ยท Tests: DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg) Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy NCT06083844Phase 22 sites๐Ÿ“ New York๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Pembrolizumab, Bevacizumab, Cyclophosphamide A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression NCT07546500Phase 359 sites๐Ÿ“ Phoenix๐Ÿ“ Antioch๐Ÿ“ Beverly Hills K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis โ€ฆ ยท Tests: Investigator's choice of Chemotherapy, Azenosertib OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy NCT06466382NA10 sites๐Ÿ“ Baden๐Ÿ“ Basel๐Ÿ“ Sankt Gallen Swiss GO Trial Group ยท Tests: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling, Carboplatin / Paclitaxel Chemotherapy A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988Phase 1, Phase 214 sites๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach๐Ÿ“ Aurora Volastra Therapeutics, Inc. ยท Tests: VLS-1488 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) NCT04111978Phase 353 sites๐Ÿ“ Graz๐Ÿ“ Graz๐Ÿ“ Innsbruck Swiss GO Trial Group ยท Tests: Letrozole 2.5mg, Placebo Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Fort Worth๐Ÿ“ West Valley City Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: EXS74539 First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites๐Ÿ“ Aurora๐Ÿ“ Sarasota๐Ÿ“ Detroit Accent Therapeutics ยท Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) A Study of Sovilnesib in Subjects With Ovarian Cancer NCT06084416Phase 111 sites๐Ÿ“ Birmingham๐Ÿ“ Little Rock๐Ÿ“ Newport Beach Volastra Therapeutics, Inc. ยท Tests: Sovilnesib Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer NCT05998135Phase 21 site๐Ÿ“ Atlanta Emory University ยท Tests: Atovaquone, Biopsy, Computed Tomography, Paracentesis Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy NCT07504588Phase 219 sites๐Ÿ“ Fayetteville๐Ÿ“ Rogers๐Ÿ“ Springdale National Cancer Institute (NCI) ยท Tests: Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322n/a6 sites๐Ÿ“ Little Rock๐Ÿ“ San Francisco๐Ÿ“ Annapolis Massachusetts General Hospital ยท Tests: Uterine lavage, or a wash of the womb, Blood sample, Pap smear A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites๐Ÿ“ Sarasota๐Ÿ“ Edgewood๐Ÿ“ Lexington AbbVie ยท Tests: Mirvetuximab Soravtansine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy